Medtech firm Senseonics' Q2 revenue up 37%, net loss narrows

Reuters
Aug 07
Medtech firm Senseonics' <a href="https://laohu8.com/S/QTWO">Q2</a> revenue up 37%, net loss narrows

Overview

  • Senseonics Q2 revenue grows 37% yr/yr to $6.6 mln, driven by U.S. patient growth

  • Net loss narrows to $14.5 mln, aided by improved gross profit margins

  • Co raises $77.8 mln to support Eversense 365 launch and pipeline development

Outlook

  • Senseonics expects 2025 revenue of $34-38 mln

  • Company projects 2025 gross margins of 32.5%-37.5%

  • Senseonics anticipates cash use of $60 mln in 2025

  • Revenue expected to be weighted to Q4 due to reorder dynamics

Result Drivers

  • U.S. PATIENT GROWTH - 79% increase in new patient starts in the U.S. drives revenue growth

  • DTC ADVERTISING - Expanded direct-to-consumer campaign boosts leads by 50%

  • GROSS PROFIT MARGINS - Improved margins on 365-day product and one-time tax gain enhance profitability

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 EPS

-$0.02

Q2 Net Income

-$14.50 mln

Q2 Gross Profit

$3.12 mln

Q2 Operating Income

-$14.32 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Senseonics Holdings Inc is $1.33, about 61.8% above its August 5 closing price of $0.51

Press Release: ID:nGNX5JVQQ8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10